

Name of Journal: *World Journal of Cardiology*

ESPS Manuscript NO: 19311

Manuscript Type: Minireviews

P2Y12-ADP receptor antagonists: days of future and past

Laine Marc, Paganelli Franck, Bonello Laurent

Abstract

Antiplatelet therapy is the cornerstone of the therapeutic arsenal in coronary artery disease. Thanks to a better understanding in physiology, pharmacology and pharmacogenomics huge progress were made in the field of platelet reactivity inhibition thus allowing the expansion of percutaneous coronary intervention. Stent implantation requires the combination of two antiplatelet agents acting in a synergistic way. Aspirin

Match Overview

1	CrossCheck 61 words Laine, Marc, Laurence Campin-Jau, Jacques Bessereau, Amaro Sebastien, Franck Paganelli, and Laurent Bonello. *	1%
2	Internet 27 words content.nejm.org	1%
3	CrossCheck 26 words Martin Moser, "Antiplatelet therapy for atherothrombotic disease: How can we improve the outcomes?", <i>Journal of Th</i>	1%
4	CrossCheck 18 words Brown, Charles, Brijen Joshi, Naudei Faraday, Ashish Shah, David Yuh, Jeffrey J. Rade, and Charles W. Hogue. "Em	<1%
5	CrossCheck 17 words De Luca, L., L. Bolognese, M. Valgimigli, R. Ceravolo, G. B. Danti, E. Piccaluga, S. Rakar, A. Cremonesi, F. M. Boven	<1%
6	CrossCheck 17 words Saucedo, Jorge Felix, "Antiplatelet therapy for patients w diabetes mellitus and acute coronary syndrome", <i>Primary</i>	<1%
7	Internet 16 words crawled on 04-Jan-2015 www.ncbi.nlm.nih.gov	<1%
8	CrossCheck 16 words Roswitha Wotfram, "Indication for Anticoagulation Post-Percutaneous Coronary Intervention", <i>Pharmacology in the C</i>	<1%

[全部](#)[图片](#)[新闻](#)[视频](#)[更多 ▾](#)[搜索工具](#)

找到约 38,600 条结果 (用时 0.60 秒)

Anti-platelet therapy: ADP receptor antagonists

www.ncbi.nlm.nih.gov > ... > [PubMed Central \(PMC\)](#) ▾ [翻译此页](#)

作者: YD Wijeyeratne - 2011 - 被引用次数: 23 - 相关文章

Here we describe the **ADP receptor antagonists** that are available and in ... Keywords: anti-platelet, cangrelor, clopidogrel, platelet, **P2Y12**, prasugrel, ticagrelor function lasts for the lifetime of the affected platelet, which is between 7 and 10 **days**. ... response may offer a cost-effective strategy in **future** antiplatelet therapy.

Platelet ADP-receptor Antagonists for CV Disease: Past ...

www.medscape.org/viewarticle/582623 ▾ [翻译此页](#)

Platelet **ADP-receptor Antagonists** for Cardiovascular Disease: **Past**, Present ... to complete the Activity Evaluation to provide feedback for **future** programming.

Pharmacodynamic Properties of Antiplatelet Agents

www.medscape.com/viewarticle/764760_3 ▾ [翻译此页](#)

What is the **future** of individualized antiplatelet therapy? ... P2Y1 is a Gq-coupled **receptor** that initiates **ADP**-induced platelet aggregation through ... Clopidogrel and prasugrel are irreversible **antagonists** of the P2Y12 **receptor**. ... The maximum inhibition of P2Y12 by clopidogrel is observed 4–5 **days** after daily administration ...

Platelet ADP-receptor antagonists for ... - Nature

www.nature.com > [Home](#) > [Archive](#) > [Vol 5 No 12](#) > [Review](#) - [翻译此页](#)

作者: NC Raju - 2008 - 被引用次数: 91 - 相关文章

Platelet **ADP-receptor antagonists** for cardiovascular disease: **past**, present and **future** ... syndromes", "**P2Y12**", "percutaneous coronary intervention", "randomized" and "clinical trials". A mean of 15 **days** of therapy with clopidogrel significantly reduced the occurrence of MI stroke. ... Conclusions and **future** perspectives



全部

图片

新闻

视频

更多 ▾

搜索工具

找到约 38,800 条结果（用时 0.60 秒）

Anti-platelet therapy: ADP receptor antagonists

www.ncbi.nlm.nih.gov > ... > [PubMed Central \(PMC\)](#) ▾ [翻译此页](#)

作者: YD Wijeyeratne - 2011 - 被引用次数: 23 - [相关文章](#)

Here we describe the **ADP receptor antagonists** that are available and in ... Keywords: anti-platelet, cangrelor, clopidogrel, platelet, **P2Y12**, prasugrel, ticagrelor function lasts for the lifetime of the affected platelet, which is between 7 and 10 **days**. ... response may offer a cost-effective strategy in **future** antiplatelet therapy.

Platelet ADP-receptor Antagonists for CV Disease: Past ...

www.medscape.org/viewarticle/582623 ▾ [翻译此页](#)

Platelet **ADP-receptor Antagonists** for Cardiovascular Disease: **Past**, Present ... to complete the Activity Evaluation to provide feedback for **future** programming.

Pharmacodynamic Properties of Antiplatelet Agents

www.medscape.com/viewarticle/764760_3 ▾ [翻译此页](#)

What is the **future** of individualized antiplatelet therapy? ... P2Y1 is a Gq-coupled **receptor** that initiates **ADP**-induced platelet aggregation through ... Clopidogrel and prasugrel are irreversible **antagonists** of the P2Y12 **receptor**. ... The maximum inhibition of P2Y12 by clopidogrel is observed 4–5 **days** after daily administration ...

Platelet ADP-receptor antagonists for ... - Nature

www.nature.com > Home > Archive > Vol 5 No 12 > Review - [翻译此页](#)

作者: NC Raju - 2008 - 被引用次数: 92 - [相关文章](#)

Platelet **ADP-receptor antagonists** for cardiovascular disease: **past**, present and **future** ... syndromes", "**P2Y12**", "percutaneous coronary intervention", "randomized" and "clinical trials". A mean of 15 **days** of therapy with clopidogrel significantly reduced the occurrence of MI, stroke Conclusions and **future** perspectives.